Unravelling Effector Functions of B cells in Infectious Diseases and Cancer

A special issue of Antibodies (ISSN 2073-4468). This special issue belongs to the section "Humoral Immunity".

Deadline for manuscript submissions: 20 November 2024 | Viewed by 551

Special Issue Editor

E-Mail Website
Guest Editor
JIS Institute of Advanced Studies and Research, JIS University, Arch Waterfront, Salt Lake, Sector V, GP Block, Kolkata 700091, India
Interests: immunotherapy; antigenic modulation; vaccine; biotherapeutic drugs

Special Issue Information

Dear Colleagues,

Infectious diseases cause significant morbidity and mortality worldwide, particularly in low- and middle-income countries. Antibodies are the cardinal effector molecules of the adaptive immune system and are being leveraged as biotherapeutic drugs against bacterial, parasitic and viral diseases and cancer. Besides direct neutralization, antibodies induce innate and adaptive immune responses (through their Fc domain) that are critical to a successful host immune response against infections as in AIDS, Ebola, malaria, influenza, tuberculosis and a host of other diseases. Diverse effector functions are deployed by antibodies such as immune complex formation that drive sequestration and uptake of pathogens, elimination of infected cells, enhancement of antigen presentation and regulation of inflammation. The antibody responses are stimulated by infected cells or parasites in the mammalian hosts and may be disease-promoting or protective depending upon the invading parasite species and the antibody isotype stimulated. The protective antibodies may inhibit parasite invasion and hence its growth via antibody-dependent cellular cytotoxicity and complement-fixing antibodies as in the case of Plasmodium species that cause malaria. Antibodies have been reported to block the entry of cestodes like Taenia and Echinococcus into the mammalian host. While intracellular parasites such as Toxoplasma, Entamoeba and Leishmania species persist in the hostile milieu of the host by mitigating the antibody effector functions. Tailored monoclonal antibody-based therapeutics may help in designing effective vaccines against these infections and cancer. The affinity and avidity of engineered antibody formats may also be tuned to enable a new wave of differentiated antibody drugs with tailored properties and novel functions, as promising treatment options for a wide variety of diseases.

This book will focus on antibodies leveraging a remarkable diversity of anti-microbial processes locked within our immune system, and the specific antibody effector functions that can be harnessed to facilitate the diagnosis, treatment and prevention of infections. The amelioration of antibody effector functions will also be discussed that may guide a rational vaccine design and antibody-based therapeutics to target gaps in our infectious disease armamentarium.

Dr. Farhat Afrin
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibodies is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • Antibody-based therapeutics
  • effector functions
  • infectious diseases
  • antibody isotypes
  • antibody-dependent cellular cytotoxicity
  • complement fixation
  • inflammation
  • vaccines
  • engineered antibodies
  • antigen presentation
  • cancer

Published Papers

This special issue is now open for submission.
Back to TopTop